Vigil Neuroscience downgraded to Underweight from Equal Weight at Morgan Stanley

Morgan Stanley analyst Matthew Harrison downgraded Vigil Neuroscience to Underweight from Equal Weight with a price target of $4, down from $13. Morgan Stanley still likes Vigil’s approach for treating neurodegenerative diseases through microglial-targeted therapeutics and still sees positive risk/reward skew, but sees better risk-adjusted opportunities elsewhere, the analyst tells investors in a research note.